Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

ACCESSWIRE10-15

DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475343803?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-15 04:15","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2475343803","market":"us","top_or_hot":-1,"title":"Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit","media":"ACCESSWIRE","content":"<div>\n<p>DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the \"Company\" or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aytu-biopharma-participate-2024-maxim-201500021.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-15 04:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/aytu-biopharma-participate-2024-maxim-201500021.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the \"Company\" or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh ...</p>\n\n<a href=\"https://finance.yahoo.com/news/aytu-biopharma-participate-2024-maxim-201500021.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4137","symbol_name":"综合支持服务","start_time":0,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-participate-2024-maxim-201500021.html","article_id":"2475343803","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475343803","pubTimestamp":1728936900,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time.Format: Fireside chatDate: Wednesday, October 16, 2024Time: 2:00 p.m. Eastern timeLocation: Virtual. To sign up to view the presentation, click here.Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT  extended-release orally disintegrating tablets  and Cotempla XR-ODT  extended-release orally disintegrating tablets  for the treatment of attention deficit hyperactivity disorder , Karbinal ER , an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4137":"综合支持服务","SMMF":"Summit Financial Group","HCSG":"医疗保健服务","ADHD":"Alcobra Ltd.","BK4007":"制药","BK4211":"区域性银行","AYTU":"Aytu BioScience, Inc."},"translate_title":"Aytu BioPharma将参加2024年Maxim Healthcare虚拟峰会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADHD":1,"HCSG":1,"SMMF":1,"AYTU":0.9},"content_text":"DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the \"Company\" or \"Aytu\") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024, at 2:00 p.m. Eastern time.\n2024 Maxim Healthcare Virtual Summit Details\nFormat: Fireside chatDate: Wednesday, October 16, 2024Time: 2:00 p.m. Eastern timeLocation: Virtual\nTo sign up to view the presentation, click here.\n1x1 investor meetings will be available after the event upon request by contacting your Maxim representative or the Company's investor relations group at aytu@lythampartners.com.\nAbout Aytu BioPharma, Inc.\nAytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit aytubio.com.\nContacts for Investors\nMark Oki, Chief Financial OfficerAytu BioPharma, Inc.moki@aytubio.com\nRobert Blum or Roger WeissLytham Partnersaytu@lythampartners.com\nSOURCE: Aytu BioPharma, Inc.\n\nView the original \npress release on accesswire.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475343803"}